A randomized study of cisplatin and 5‑FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

Authors
Myeong Jun SongSi Hyun BaeHo Jong ChunJong Young ChoiSeung Kew YoonJun Young ParkKwang Hyub HanYoung Seok KimHyung Joon YimSoon Ho UmWoo Jin ChungJae Seok HwangSung‑Bum ChoJong Ryul Eun
Department
Dept. of Internal Medicine (내과학)
Issue Date
2015
Citation
Cancer Chemotherapy and Pharmacology, Vol.75(4) : 739-746, 2015
ISSN
0344-5704
Abstract
Purpose : This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients. Methods : Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m2 on day 1, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints. Results : Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95 % CI 2.580–16.064)] was independently associated with OS. Age (≥60 years) and serum AFP level (≥200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95 % CI 1.543–15.850), P = 0.048, HR 2.677 (95 % CI 1.010–7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups. Conclusions : Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC. Keywords : Hepatocellular carcinoma – Hepatic arterial infusion chemotherapy – 5-Fluorouracil – Cisplatin
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35291
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
정우진; 황재석
Full Text
http://lps3.link.springer.com.proxy.dsmc.or.kr/article/10.1007%2Fs00280-015-2692-0
File in this Item
 사서에게 요청하기
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE